CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Biological: CR002 Liquid API
Biological: Placebo

First Posted Date: 2011-05-04

Last Posted Date: 2012-04-05

Lead Sponsor: CSL Behring

Target Recruit Count: 25

Registration Number: NCT01347190

Locations: 🇵🇱
Site 20, Rabka Zdroj, Poland
🇵🇱
Site 24, Bialystok, Poland
🇧🇬
Site 11, Sofia, Bulgaria

and more 8 locations

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Phase 1

Completed

Conditions: Hemophilia B

Interventions: Biological: Recombinant Coagulation Factor IX Albumin Fusion Protein
Biological: Plasma derived FIX [pdFIX]

First Posted Date: 2010-11-03

Last Posted Date: 2012-01-31

Lead Sponsor: CSL Behring

Target Recruit Count: 25

Registration Number: NCT01233440

Locations: 🇮🇹
Study site, Milan, Italy
🇪🇸
Study Site, Madrid, Spain

Study of Biostate® in Children With Hemophilia A

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Biological: Biostate

First Posted Date: 2010-10-27

Last Posted Date: 2017-08-24

Lead Sponsor: CSL Behring

Target Recruit Count: 35

Registration Number: NCT01229007

Locations: 🇲🇽
Study site, Monterrey, Mexico
🇺🇦
Study Site, Lviv, Ukraine

Extension Study of Biostate in Subjects With Von Willebrand Disease

Phase 3

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: Biostate

First Posted Date: 2010-10-20

Last Posted Date: 2017-10-03

Lead Sponsor: CSL Behring

Target Recruit Count: 20

Registration Number: NCT01224808

Locations: 🇺🇦
Study Site, Lviv, Ukraine

Study of Biostate® in Children With Von Willebrand Disease

Phase 3

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: Biostate

First Posted Date: 2010-10-04

Last Posted Date: 2017-10-03

Lead Sponsor: CSL Behring

Target Recruit Count: 17

Registration Number: NCT01213446

Locations: 🇱🇧
Study site, Beirut, Lebanon
🇺🇦
Study Site, Lviv, Ukraine

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Phase 3

Completed

Conditions: Primary Immune Deficiency

Interventions: Biological: Immune Globulin Subcutaneous (Human) (SCIG)

First Posted Date: 2010-09-13

Last Posted Date: 2014-12-12

Lead Sponsor: CSL Behring

Target Recruit Count: 25

Registration Number: NCT01199705

Locations: 🇯🇵
Study site, Tokorozawa city, Saitama Pref., Japan

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Phase 3

Completed

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Interventions: Biological: 10% liquid formulation of human immunoglobulin

First Posted Date: 2010-08-19

Last Posted Date: 2024-06-25

Lead Sponsor: CSL Behring

Target Recruit Count: 31

Registration Number: NCT01184846

Locations: 🇵🇱
Study Site, Wroclaw, Poland

Retrospective Chart Review of Subcutaneous IgG Use in Infants

Completed

Conditions: Primary Immune Deficiency

Interventions: Biological: Subcutaneous IgG (SCIG)

First Posted Date: 2010-07-20

Last Posted Date: 2011-02-11

Lead Sponsor: CSL Behring

Target Recruit Count: 27

Registration Number: NCT01166074

Locations: 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Midwest Immunology Clinic, Plymouth, Minnesota, United States
🇺🇸
University of South Florida, Tampa, Florida, United States

and more 2 locations

Patient Registry Study of Berinert® in Normal Clinical Practice

Completed

Conditions: Includes: Hereditary Angioedema

Interventions: Biological: Berinert® (C1 Esterase Inhibitor)

First Posted Date: 2010-04-22

Last Posted Date: 2014-06-09

Lead Sponsor: CSL Behring

Target Recruit Count: 318

Registration Number: NCT01108848

Locations: 🇺🇸
United States, New York, North Syracuse, New York, United States
🇺🇸
United States, Oklahoma, Tulsa, Oklahoma, United States
🇺🇸
United States, Washington, Tacoma, Washington, United States

and more 23 locations

Rabies Immune Plasma Booster Study

Completed

Conditions: Rabies

Interventions: Biological: Rabies Vaccine (RabAvert)
Biological: Rabies Vaccine (Imovax)

First Posted Date: 2010-02-05

Last Posted Date: 2015-09-07

Lead Sponsor: CSL Behring

Target Recruit Count: 491

Registration Number: NCT01063140

Locations: 🇺🇸
CSL Donor Plasma Center, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy